subject: Aarkstore Enterprise---iris International, Inc. (iris) - Financial And Strategic Analysis Review [print this page] IRIS International, Inc. (IRIS) designs, develops, manufactures and markets in-vitro diagnostic imaging products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The company operates through two reportable business segments, namely, In-Vitro Diagnostics (IVD) and Sample Processing segment. In addition, it also offers products in relation with cytology, hematology, and urinalysis for the clinical and veterinary markets. It conducts its business operations through three operating subsidiaries namely Advanced Digital Imaging Research (ADIR), Iris Molecular Diagnostics (IMD) and IRIS Sample Processing.
IRIS International, Inc. Key Recent Developments
May 13, 2010: IRIS International Corporate Vice President And CFO Peter L. Donato Resigns
Apr 26, 2010: IRIS Renews Supply Agreement With MedAssets For Urinalysis Product Line And Related Products
Mar 01, 2010: IRIS International Reports Net Income Of $6.3 Million In 2009
Feb 25, 2010: IRIS International Signs Three-Year Agreement With HealthTrust
Jan 19, 2010: IRIS International Signs Strategic Partnership With Digital Images Diagnostic To Market Its Complete Urinalysis Product Line In China
This comprehensive SWOT analysis of IRIS International, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
